The Human Papillomavirus E2 Protein

Abstract

The human papillomavirus (HPV) is the predominant viral infection of the reproductive system, leading to a range of diseases in both males and females, including precancerous lesions that have the potential to develop into cancer. Certain HPV infections can cause the development of genital warts, while others can lead to the formation of abnormal cells that have the potential to progress into cancer. Although preventative vaccines are accessible and have shown encouraging outcomes, the worldwide occurrence and death rates of HPV-related malignancies continue to be elevated, especially in low- and middle-income nations. Currently, there is no known remedy for HPV infection, and innovative therapeutic methods such as immunotherapy have emerged as successful tactics for treating and eradicating malignancies caused by the virus. The oncoproteins E6 and E7 have been widely employed in early immunotherapies, such as HPV therapeutic vaccines, with the goal of treating related illnesses and cancers by inducing a strong cellular immune response to eradicate infected cells.Moreover, the E2 protein shows great potential in the advancement of HPV therapeutic vaccines because of its crucial function in controlling viral gene expression and replication. This publication provides an overview of the HPV genome and emphasizes the crucial significance of the E2 protein in the life cycle of HPV. We provide an overview of the present state of E2-targeting techniques and examine their potential for use in cancer therapy.